SHANGHAI – Suzhou-based Innovent Biologics Inc. and Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea, will pair up to co-develop and co-commercialize a bispecific immuno-oncology antibody for breast cancer with the possibility of other indications to follow. The molecule is expected to enter clinical trials in 2019.